| Systemic weakness after therapeutic injections of botulinum toxin a: a case series and review of the literature. | |
| | |
MedLine Citation:
|
PMID: 20852412 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The use of intramuscular injections of Botulinum neurotoxin A (BoNT-A) is common in the treatment of hypertonicity and movement disorders. Although most side effects are mild, systemic effects, manifested by generalized weakness distant from the site of injection, have been reported. Previously reported occurrences are discussed, and 3 new cases of patients, who developed systemic weakness after administration of BoNT-A (Botox), despite having tolerated similar injections on several previous occasions, are presented. A review of the literature and reported cases indicate that risk of developing systemic effects does not seem to be related to dose based on body weight. It may be more likely that risk for systemic effects is related to total injection dose and injection frequency. The results of our 3 patients would indicate that injections of greater than 600 units of Botox with follow-up injections occurring every 3 months may lead to an increased risk. We would recommend careful consideration of reinjection frequency if injections of greater than 600 units of Botox are given. Reduction in systemic side effects may occur if reinjection frequency occurs in intervals of 4 months or greater in these individuals. |
| | |
Authors:
|
Beth E Crowner; Diego Torres-Russotto; Alexandre R Carter; Brad A Racette |
Publication Detail:
|
Type: Case Reports; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review |
Journal Detail:
|
Title: Clinical neuropharmacology Volume: 33 ISSN: 1537-162X ISO Abbreviation: Clin Neuropharmacol Publication Date: 2010 Sep-Oct |
Date Detail:
|
Created Date: 2010-09-24 Completed Date: 2011-01-06 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7607910 Medline TA: Clin Neuropharmacol Country: United States |
Other Details:
|
Languages: eng Pagination: 243-7 Citation Subset: IM |
Affiliation:
|
Program in Physical Therapy, Washington University School of Medicine, St. Louis, MO 63108, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adolescent Adult Anti-Dyskinesia Agents / adverse effects*, contraindications, therapeutic use Botulinum Toxins / adverse effects*, contraindications, therapeutic use Dose-Response Relationship, Drug Dystonia / drug therapy*, physiopathology Electromyography Female Humans Injections, Intramuscular Male Muscle Weakness / etiology*, physiopathology Young Adult |
| Grant Support | |
ID/Acronym/Agency:
|
1K08NS064365-01A1/NS/NINDS NIH HHS; 5T32NS007205-27/NS/NINDS NIH HHS; K24ES017765/ES/NIEHS NIH HHS; KL2RR024994/RR/NCRR NIH HHS; UL1 RR024992/RR/NCRR NIH HHS; UL1RR024992/RR/NCRR NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Anti-Dyskinesia Agents; EC 3.4.24.69/Botulinum Toxins |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Bupropion for depression in schizophrenia.
Next Document: The effect of a clinically practical exercise on levodopa bioavailability and motor response in pati...